Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21775493 | 0.83 | KMT2A (0.41) | LMNAADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL11130584 | 0.83 | LMNA (0.52) | LMNAMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL20553516 | 0.82 | LMNA (0.42) | LMNAMTNR1AMTNR1BADRB2ADRB1 | |
| SCHEMBL20552868 | 0.81 | PPARG (0.43) | LMNAADRB2ADRB1CYP2D6ADRB3 | |
| SCHEMBL21775503 | 0.81 | MTNR1B (0.49) | MTNR1AMTNR1BALDH1A1KDM4ECHRNB4 | |
| SCHEMBL11513409 | 0.81 | ADRB2 (0.48) | LMNAADRB2ADRB1ADRB3MEN1 | |
| SCHEMBL2585659 | 0.79 | PPARG (0.39) | LMNAADRB2ADRB1CYP2D6ADRB3 | |
| SCHEMBL9628819 | 0.79 | PTGS2 (0.44) | LMNAADRB3CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11201885 | 0.77 | CASR (0.43) | LMNAMTNR1AMTNR1BADRB2ADRB1 | |
| SCHEMBL11019566 | 0.77 | KMT2A (0.49) | LMNAMTNR1AMTNR1BCYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| CN-110831584-A | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2020-02-21 | — | — | CN | disclosed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | disclosed |
| EP-0193227-B1 | PROCESS FOR THE PREPARATION OF ARYLGLYCIDYL ETHERS AND 3-SUBSTITUTED 1-ALKYLAMINO-2-PROPANOLS | GIST-BROCADES N.V. (NL) | 1990-04-11 | — | — | EP | disclosed |
| EP-0193227-A1 | Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols | GIST-BROCADES N.V. (NL) | 1986-09-03 | — | — | EP | disclosed |
| EP-0013258-B1 | PROPENYL-SUBSTITUTED PHENOLGLYCIDYL ETHERS, PROCESS FOR THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | LMNA 1421/4885MTNR1A 178/4885MTNR1B 139/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | LMNA 2085/4885MTNR1A 99/4885MTNR1B 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.